Page 166 - First Aid for the USMLE Step 1 2020, Thirtieth edition [MedicalBooksVN.com]_Neat

122 SECTIon II Immunology ` Immunology—ImmunoSuppreSSantS

Therapeutic antibodies
agent target clInIcal uSe noteS
Cancer therapy
Alemtuzumab CD52 CLL, multiple sclerosis “Alymtuzumab”—chronic
lymphocytic leukemia
Bevacizumab VEGF Colorectal cancer, renal cell Also used for neovascular age-
carcinoma, non-small cell related macular degeneration,
lung cancer proliferative diabetic
retinopathy, and macular
edema
Rituximab CD20 B-cell non-Hodgkin Risk of PML in patients with
lymphoma, CLL, rheumatoid JC virus
arthritis, ITP, multiple CD20—“ri2ximab”
sclerosis
Trastuzumab HER2 Breast cancer, gastric cancer HER2—“tras2zumab”
Autoimmune disease therapy
Adalimumab, Soluble TNF-α IBD, rheumatoid arthritis, Etanercept is a decoy
infliximab ankylosing spondylitis, TNF-α receptor and not a
psoriasis monoclonal antibody
Eculizumab Complement protein C5 Paroxysmal nocturnal
hemoglobinuria
Ixekizumab, IL-17A Psoriasis, psoriatic arthritis
secukinumab
Natalizumab α4-integrin Multiple sclerosis, Crohn α4-integrin: WBC adhesion
disease Risk of PML in patients with
JC virus
Ustekinumab IL-12/IL-23 Psoriasis, psoriatic arthritis
Other applications
Abciximab Platelet glycoproteins IIb/IIIa Antiplatelet agent for ABC is as easy as 123
prevention of ischemic
complications in patients
undergoing percutaneous
coronary intervention
Denosumab RANKL Osteoporosis; inhibits osteoclast Denosumab helps make dense
maturation (mimics bones
osteoprotegerin)
Omalizumab IgE Refractory allergic asthma;
prevents IgE binding to FcεRI
Palivizumab RSV F protein RSV prophylaxis for high-risk PaliVIzumab—VIrus
infants

FAS1_2019_02-Immunology.indd 122 11/7/19 3:24 PM